Correlation of Serum Endocan Level With Apoptosis Indicators and Severity of Atherosclerotic Lesions of Coronary Arteries in Patients With Coronary Heart Disease

Aim    To study the relationship of blood serum concentration of endocan with indexes of apoptosis and clinical and instrumental characteristics of patients with ischemic heart disease (IHD).
Material and methods    The study included 176 subjects (105 men and 71 women). 150 of them were diagnosed with IHD and 26 were healthy volunteers. Anthropometric measurements, coronary angiography, echocardiography, duplex ultrasound scanning of extracranial parts of the brachiocephalic arteries were performed for all patients. Concentrations of endocan (ng / ml), glucose (mmol / l), and apoptotic markers Bcl-2 (ng / ml), Bax (ng / ml), Bcl-2 / Bax, TRAIL (pg / ml), and p53 (ng / ml) were measured in blood serum. Patients were divided into groups based on their SYNTAX scores: group 1 with moderate atherosclerotic lesions of the coronary arteries (CA) (score < 22, 78 patients); group 2 with severe CA atherosclerosis (score 23-32, 37 patients); and group 3 with extremely severe CA lesions (score >33, 35 patients). The control group consisted of healthy volunteers (26 subjects). All groups were age- and sex-matched. Differences were considered statistically significant at p<0.05.
Results    A correlation was found between endocan concentration and IHD severity (r=0.32, p<0.001). In group 1, the median endocan concentration was 14.57 ng / ml [8.21; 23.66], in group 2, 19.34 ng / ml [8.425; 26.645], in group 3, 32.13 ng / ml [18.2; 39.12], and in the control group, 6.92 ng / ml [4.62; 9.18]. Correlations of varying strength and significance were observed between the endocan concentration and a number of clinical and instrumental characteristics. Endocan concentrations significantly differed in groups of patients with multifocal atherosclerosis (p<0.01), angina pectoris (p<0.01), a history of myocardial infarction (p<0.001), and obesity (p<0.05) from patients without these signs. Also, a correlation was found between serum endocan concentration and apoptotic markers: TRAIL (r= -0.448, p<0.001); BCL-2 (r= -0.552, p<0.001), Bax (r= -0.519, p<0.001), Bcl-2 / Bax (r= -0.576, p<0.001) and p53 (r= -0.520, p <0.001).
Conclusion    The study demonstrated a potential role of endocan as a promising biomarker for risk stratification, prognosis and therapeutic monitoring of IHD patients.

1. Balta S, Balta I, Mikhailidis DP. Endocan: a new marker of endothelial function. Current Opinion in Cardiology. 2021;36(4):462–8. DOI: 10.1097/HCO.0000000000000867

2. Chen J, Jiang L, Yu X-H, Hu M, Zhang Y-K, Liu X et al. Endocan: A Key Player of Cardiovascular Disease. Frontiers in Cardiovascular Medicine. 2022;8:798699. DOI: 10.3389/fcvm.2021.798699

3. Khalaji A, Behnoush AH, Saeedian B, Khanmohammadi S, Shokri Varniab Z, Peiman S. Endocan in prediabetes, diabetes, and diabetesrelated complications: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2023;15(1):102. DOI: 10.1186/s13098-023-01076-z

4. Klisic A, Patoulias D. The Role of Endocan in Cardiometabolic Disorders. Metabolites. 2023;13(5):640. DOI: 10.3390/metabo13050640

5. Klisic A, Kavaric N, Vujcic S, Spasojevic-Kalimanovska V, Ninic A, Kotur-Stevuljevic J. Endocan and advanced oxidation protein products in adult population with hypertension. European Review for Medical and Pharmacological Sciences. 2020;24(12):7131–7. DOI: 10.26355/eurrev_202006_21707

6. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M et al. Endocan—A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension: A Pilot Study. Angiology. 2014;65(9):773–7. DOI: 10.1177/0003319713513492

7. Oktar SF, Guney I, Eren SA, Oktar L, Kosar K, Buyukterzi Z et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clinical and Experimental Hypertension. 2019;41(8):787–94. DOI: 10.1080/10641963.2019.1652632

8. Zhao T, Kecheng Y, Zhao X, Hu X, Zhu J, Wang Y et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine. 2018;97(49):e13407. DOI: 10.1097/MD.0000000000013407

9. Kundi H, Balun A, Cicekcioglu H, Karayigit O, Topcuoglu C, Kilinckaya MF et al. Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction. Angiology. 2017;68(1):46–51. DOI: 10.1177/0003319716646932

10. Çimen T, Efe TH, Akyel A, Sunman H, Algül E, Şahan HF et al. Human Endothelial Cell-Specific Molecule-1 (Endocan) and Coronary Artery Disease and Microvascular Angina. Angiology. 2016;67(9):846–53. DOI: 10.1177/0003319715625827

11. Bessa J, Albino-Teixeira A, Reina-Couto M, Sousa T. Endocan: A novel biomarker for risk stratification, prognosis and therapeutic mo nitoring in human cardiovascular and renal diseases. Clinica Chimica Acta. 2020;509:310–35. DOI: 10.1016/j.cca.2020.07.041

12. Klisić A, Kavarić N, Spasojević-Kalimanovska V, Kotur-Stevuljević J, Ninić A. Serum endocan levels in relation to traditional and non-traditional anthropometric indices in adult population. Journal of Medical Biochemistry. 2021;40(1):41–8. DOI: 10.5937/jomb0-25170

13. Elkamshoushi AM, Omar SS, El Abd AM, Hassan SZ, Sultan EA, Abd Elkawy E. Subclinical atherosclerosis in psoriatic disease: relation to endocan, TNF‐α, age of onset, and body fat. International Journal of Dermatology. 2019;58(4):456–64. DOI: 10.1111/ijd.14290

14. Delibas IB, Yapca OE, Laloglu E. Does endocan level increase in women with polycystic ovary syndrome? A case – control study. Ginekologia Polska. 2018;89(9):500–5. DOI: 10.5603/GP.a2018.0085

15. Federico A, Dallio M, Masarone M, Gravina AG, Di Sarno R, Tuccillo C et al. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. Oxidative Medicine and Cellular Longevity. 2019;2019:8742075. DOI: 10.1155/2019/8742075

16. Behnoush AH, Khalaji A, Amirkhani N, Pezeshki PS. Diagnostic Role of Circulating Endocan Levels in Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. Angiology. 2023;000331972311830. [Epub ahead of print]. DOI: 10.1177/00033197231183087

17. Leite AR, Borges-Canha M, Cardoso R, Neves JS, Castro-Ferreira R, Leite-Moreira A. Novel Biomarkers for Evaluation of Endothelial Dysfunction. Angiology. 2020;71(5):397–410. DOI: 10.1177/0003319720903586

18. Grigor’ev V.S., Petrosyan K.V., Abrosimov A.V. Anatomical SYNTAX Score: a tool for coronary artery disease severity assessment and predicting endovascular treatment outcomes. Creative Cardiology. 2019;13(2):159–72. DOI: 10.24022/1997-3187-2019-13-2-159-172

19. Balta S. Endothelial Dysfunction and Inflammatory Markers of Vascular Disease. Current Vascular Pharmacology. 2020;19(3):243–9. DOI: 10.2174/1570161118666200421142542

20. Ambrosino P, Bachetti T, D’Anna SE, Galloway B, Bianco A, D’Agnano V et al. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. Journal of Cardiovascular Development and Disease. 2022;9(5):136. DOI: 10.3390/jcdd9050136

21. Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, González-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. International Journal of Molecular Sciences. 2021;22(8):3850. DOI: 10.3390/ijms22083850

22. Zakharyan E.A., Ageeva E.S., Shramko Yu.I., Malyi K.D., Gurtovaya A.K., Ibragimova R.E. A modern view on the diagnostic role of endothelial dysfunction biomarkers and the possibilities of its correction. Complex Issues of Cardiovascular Diseases. 2022;11(4S):194–207. DOI: 10.17802/2306-1278-2022-11-4S-194-207

23. Xiong C, Zhao Z, Chen Z, Wu L, Luo Y, Hu F et al. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association with Coronary Artery Disease in Patients with Hypertension. Journal of Investigative Medicine. 2015;63(7):867–70. DOI: 10.1097/JIM.0000000000000219

24. Küp A, Toprak C, Bayam E, İzcı S, Abdulkadir Uslu, Çelık M et al. Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris. Acta Cardiologica Sinica. 2020;36(2):111–7. DOI: 10.6515/ACS.202003_36(2).20190731A

25. Dong Y, Chen H, Gao J, Liu Y, Li J, Wang J. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. Journal of Molecular and Cellular Cardiology. 2019;136:27–41. DOI: 10.1016/j.yjmcc.2019.09.001

26. Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66(8):727–31. DOI: 10.1177/0003319714548870

27. Qiu C-R, Fu Q, Sui J, Zhang Q, Wei P, Wu Y et al. Serum Endothelial Cell–Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance: A Pilot Study. Angiology. 2017;68(4):354–9. DOI: 10.1177/0003319716651349

28. Maksimovic M, Vlajinac H, Radak D, Marinkovic J, Maksimovic J, Jorga J. Association of overweight and obesity with cardiovascular risk factors in patients with atherosclerotic diseases. Journal of Medical Biochemistry. 2019;39(2):215–23. DOI: 10.2478/jomb-2019-0027

29. Bicer M, Guler A, Unal Kocabas G, Imamoglu C, Baloglu A, Bilgir O et al. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocrine Research. 2017;42(2):145–53. DOI: 10.1080/07435800.2016.1255896

30. Janke J, Engeli S, Gorzelniak K, Feldpausch M, Heintze U, Böhnke J et al. Adipose Tissue and Circulating Endothelial Cell Speci fic Molecule-1 in Human Obesity. Hormone and Metabolic Research. 2006;38(1):28–33. DOI: 10.1055/s-2006-924973

31. Klisic A, Kavaric N, Stanisic V, Vujcic S, Spasojevic-Kalimanovska V, Ninic A et al. Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes. Archives of Medical Science. 2020;16(1):42–50. DOI: 10.5114/aoms.2019.87541

32. Belongie KJ, Ferrannini E, Johnson K, Andrade-Gordon P, Hansen MK, Petrie JR. Identification of novel biomarkers to monitor β-cell function and enable early detection of type 2 diabetes risk. PLoS One. 2017;12(8):e0182932. DOI: 10.1371/journal.pone.0182932